Clinical Trial: Guanfacine to Treat Borderline Personality Disorder
Study Status: Recruiting
Recruit Status: Unknown status
Study Type: Interventional
Official Title: Guanfacine in the Treatment of Borderline Personality Disorder
Brief Summary: This study is designed to investigate whether guanfacine (Tenex) is an effective treatment for borderline personality disorder (BPD), an illness often characterized by unstable mood and impulsive aggression. Guanfacine stimulates activity in the front portion of the brain, a region associated with attention and the control of behavior. We believe that guanfacine may improve symptoms of BPD by improving attention and aiding regulation of behavior.
Detailed Summary: This is an 8-week treatment study designed to test whether guanfacine is an effective treatment for borderline personality disorder (BPD). Prior to taking the study medication, subjects will have medical and psychiatric evaluations, complete self-report questionnaires, do a functional MRI scan, and complete a set of cognitive tests. While taking the study medication, participants will meet weekly with a study doctor and be administered interviews and questionnaires. At the end of the 8-week trial, participants will be asked to repeat the MRI scan and cognitive tests.
Sponsor: Icahn School of Medicine at Mount Sinai
Current Primary Outcome:
- measures of impulsive aggression
- measures of affective disturbance
- measures of social and occupational functioning
- measures of overall clinical status
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Bronx VA Medical Center
Dates:
Date Received: July 31, 2006
Date Started: July 2006
Date Completion:
Last Updated: July 31, 2006
Last Verified: July 2006
